RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
CEO & Chairman
Dror Ben-Asher co-founded RedHill and serves as the Company’s CEO and Chairman, bringing extensive managerial and transactional expertise. He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed his LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department.
Dror received an LL.B. with distinction (First Class Honors) from the University of Leicester.